Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).

@article{GonzlezSales2012PopulationPA,
  title={Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).},
  author={Mario Gonz{\'a}lez-Sales and Bel{\'e}n Valenzuela and Carlos P{\'e}rez-Ruixo and Carlos Fern{\'a}ndez Teruel and Bernardo Miguel-Lillo and Arturo Soto-Matos and Juan Jos{\'e} P{\'e}rez-Ruixo},
  journal={Clinical pharmacokinetics},
  year={2012},
  volume={51 11},
  pages={751-64}
}
BACKGROUND AND OBJECTIVE PM00104 (Zalypsis(®)) is a novel marine-derived compound that has shown antineoplastic activity against a number of human tumour cell lines. Myelosuppression was found to be a PM00104 dose-limiting toxicity during phase I studies. The objective of this study was to characterize the time course of neutropenia after intravenous PM00104 administration in cancer patients. METHODS Absolute neutrophil counts (ANCs) and pharmacokinetic data from 144 patients receiving… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…